SYH2092 / CSPC Pharma, AstraZeneca - LARVOL DELTA

CSPC Pharmaceutical…is pleased to announce that the Phase I clinical trial of the SYH2092 injection (the 'Product') developed by the Group for weight management in adult patients with overweight or obesity has been officially initiated at the first centre in China (HKEXnews) - "The Group obtained the Notice of Approval for Clinical Trial of Drug from the National Medical Products Administration of the People’s Republic of China in August 2026, and initiated the Phase I clinical trial of the Product following the approval. This Phase I clinical trial aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of the Product in healthy participants."

Trial status • Obesity

A Study of SYH2092 Injection in Healthy Participants (clinicaltrials.gov) - P1 | N=46 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

New P1 trial • Genetic Disorders • Obesity